Innate Pharma SA (IPHA) shareholders
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.49−0.10 (-6.29%)
Close on Nov 12, 2026Market cap $139.64MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
10
3 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sanofi | 8,345,387 | 9.05% | 13G (passive) amendment | Apr 23, 2025 |
| AstraZeneca PLC Joint filing with MedImmune Limited (8.30%) | 7,825,501 | 8.30% | 13D (active) amendment | Dec 22, 2025 |
| Caisse des depots et consignations Joint filing with Bpifrance Participations S.A. (6.90%), EPIC Bpifrance (6.90%) and 1 more | 7,319,429 | 7.90% | 13D (active) amendment | Apr 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IPHA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lion Point Capital, LP | 81,151 | – | $149.32K | – | 0.71% |
| Morgan Stanley | 43,524 | – | $80.08K | – | 0.00% |
| SmartHarvest Portfolios, LLC | 23,750 | – | $43.70K | New | 0.01% |
| XTX Topco Ltd | 15,130 | – | $27.84K | New | 0.00% |
| Citadel Advisors LLC | 12,441 | – | $22.89K | New | 0.00% |
| Jane Street Group, LLC | 10,310 | – | $18.97K | −33,055 | 0.00% |
| Rhumbline Advisers | 4,719 | – | $8.68K | −15 | 0.00% |
| UBS Group AG | 1,363 | – | $2.51K | +502 | 0.00% |
| Farther Finance Advisors, LLC | 21 | – | $38 | +11 | 0.00% |
| GAMMA Investing LLC | 9 | – | $17 | −231 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 3 / 2 | 3 / 2 | 0M | 0M |
| Q1 2026 | 9 | 0M | 1 / 0 | 6 / 3 | 0M | 0M |
| Q4 2025 | 11 | 0M | 5 / 1 | 4 / 3 | 0M | 0M |
| Q3 2025 | 9 | 0M | 1 / 1 | 3 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 1 / 3 | 3 / 2 | 0M | 0M |
| Q1 2025 | 10 | 0M | 3 / 2 | 1 / 2 | 0M | 0M |
| Q4 2024 | 9 | 0M | 1 / 1 | 3 / 0 | 0M | 0M |
| Q3 2024 | 8 | 0M | 0 / 1 | 4 / 0 | 0M | 0M |
| Q2 2024 | 8 | 0M | 1 / 2 | 2 / 2 | 0M | 0M |
| Q1 2024 | 9 | 0M | 1 / 4 | 1 / 0 | 0M | 0M |
| Q4 2023 | 8 | 0M | 0 / 2 | 3 / 0 | 0M | 0M |
| Q3 2023 | 8 | 0M | 0 / 1 | 3 / 1 | 0M | 0M |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
8.9
At 0M shares a day
Change since last report
-2.9%
From 0M shares
Short volume, 20 days
55.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Innate Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,568 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?